Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates

Azathioprine and mercaptopurine are considered safe during pregnancy. However, the pharmacokinetic effects of pregnancy on thiopurine metabolism are undefined.

[1]  D. Kurnik,et al.  Thiopurine hepatotoxicity can mimic intrahepatic cholestasis of pregnancy. , 2020, Clinics and research in hepatology and gastroenterology.

[2]  W. Hardikar,et al.  Lower 6-MMP/6-TG Ratio May Be a Therapeutic Target in Pediatric Autoimmune Hepatitis , 2018, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

[3]  C. Joyau,et al.  A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn’s Disease , 2018, Journal of Crohn's & colitis.

[4]  N. D. de Boer,et al.  Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  C. Chambers,et al.  Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[6]  Jiezhun Gu,et al.  Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes , 2017, Journal of clinical gastroenterology.

[7]  Steven J Brown,et al.  Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. , 2016, Gastroenterology.

[8]  A. Ananthakrishnan,et al.  New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease , 2015, Alimentary pharmacology & therapeutics.

[9]  C. J. van der Woude,et al.  The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.

[10]  K. Vakili,et al.  Neonatal liver physiology. , 2013, Seminars in pediatric surgery.

[11]  J. Mate,et al.  Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease , 2013, The American Journal of Gastroenterology.

[12]  D. Hommes,et al.  Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease , 2013, Gut.

[13]  P. Rutgeerts,et al.  Review article: non‐malignant haematological complications of anti‐tumour necrosis factor alpha therapy , 2012, Alimentary pharmacology & therapeutics.

[14]  R. Gearry,et al.  Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.

[15]  F. Carrat,et al.  Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study , 2009, Gut.

[16]  C. J. van der Woude,et al.  Azathioprine treatment during lactation , 2009, Alimentary pharmacology & therapeutics.

[17]  J. Mate,et al.  Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review , 2007, The American Journal of Gastroenterology.

[18]  R. Gearry,et al.  Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. , 2006, British journal of clinical pharmacology.

[19]  S. Soldin,et al.  Pediatric Reference Intervals , 2005 .

[20]  C. Dame,et al.  Primary and secondary thrombocytosis in childhood , 2005, British journal of haematology.

[21]  K. Michaelsen,et al.  Does Breast Feeding Influence Liver Biochemistry? , 2003, Journal of pediatric gastroenterology and nutrition.

[22]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.